Spyre Therapeutics (SYRE)
Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.
Something off on this page? Send us feedback.
Develops extended-half-life antibody monotherapies and combinations for inflammatory bowel disease, rheumatic diseases, and hidradenitis suppurativa. With no marketed products or product-sales revenue, the business depends on advancing licensed programs through trials and regulatory review.
Develops extended-half-life monoclonal antibodies and combinations for immune-mediated diseases, with programs spanning gastroenterology, rheumatology, and dermatology. SKYLINE evaluates SPY001, SPY002, SPY003, and pairwise combinations SPY120, SPY130, and SPY230 in ulcerative colitis.
SKYWAY tests SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The newer SPY772 program pairs SPY072 with preclinical SPY007 for hidradenitis suppurativa. Candidates are engineered for longer exposure, concentrated formulations, and infrequent subcutaneous maintenance dosing.
Operates from Waltham while running trials in the United States and Europe. No product is approved or sold; development depends on clinical execution, regulatory review, licensed rights from Paragon Therapeutics, and outsourced manufacturing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Robert W. Baird | Target | Target: $120 | Target: $116 |
| Aug 27, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $130 |
| Aug 26, 2026 | Wedbush | Reiterate | Rating: —Target: $130 | Target: $123 |
| Aug 26, 2026 | BTIG | Reiterate | Rating: —Target: $112 | Target: $121 |
| Aug 26, 2026 | Deutsche Bank | Reiterate | Rating: —Target: $135 | Target: $127 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.15B · Total debt $0 · Total assets $1.17B · Shareholders' equity $1.10B
- Revenue
- $0
- Operating income
- −$41.6M
- Net income
- −$36.2M
No dividends on record.
| Institutions | ≈ 107.30% | 94.61M shares | |
|---|---|---|---|
| 276 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.81% | 713.1K shares | |
| 5 holders · as of Sep 3, 2026 | |||
| Adds to | 108.11% | ||
88.17M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 108.11%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.77% | 13.03M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.38% | 6.51M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 4.90% | 4.32M | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 4.82% | 4.25M | as of Jun 30, 2026 |
Paradigm Biocapital Advisors LPInstitution | 4.36% | 3.84M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Cameron Turtle | director, officer: Chief Executive Officer | −15,000 | $87.29 |
| Sep 2, 2026 | Scott L. Burrows | officer: Chief Financial Officer | −18,232 | $89.35 |
| Sep 1, 2026 | Scott L. Burrows | officer: Chief Financial Officer | −7,500 | $87.31 |
| Sep 2, 2026 | Heidy King-Jones | officer: See Remarks | −400 | $90.00 |
| Sep 1, 2026 | Heidy King-Jones | officer: See Remarks | −27,999 | $87.31 |
- AbbVie
Broad immunology incumbent across IBD and rheumatology
- Johnson & Johnson
Broad immunology incumbent across IL-23, TNF, and IBD biologics
- Takeda (ADR)
Alpha4beta7 IBD incumbent via Entyvio
- Eli Lilly
IL-23 IBD, anti-integrin IBD, and PsA/axSpA overlap
- Merck
Direct TL1A pipeline overlap in IBD and rheumatology
- Pfizer
Oral UC alternatives plus p40/TL1A pipeline overlap
- Sanofi (ADR)
Direct TL1A IBD peer plus RA biologic overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Spyre Therapeutics | $86.68 | −5.75% | $7.99B | — | — | 88.3 | — |
| AbbVie | $264.75 | −0.17% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Johnson & Johnson | $268.43 | −0.28% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Takeda (ADR) | $18.84 | −0.61% | $60.30B | 52.9 | 59.9 | 2.0 | +4.2% |
| Eli Lilly | $1,154.59 | −1.33% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Merck | $147.26 | −2.42% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Pfizer | $28.01 | +0.27% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Sanofi (ADR) | $41.61 | −2.13% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Median | 52.9 | 20.0 | 5.6 | +6.6% |